跳到主要內容

臺灣博碩士論文加值系統

(44.200.27.215) 您好!臺灣時間:2024/04/15 04:39
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::

詳目顯示

我願授權國圖
: 
twitterline
研究生:莊叡豐
研究生(外文):Ruei-Feng Chuang
論文名稱:應用硫代乙醯胺建立肝纖維化齧齒類動物模式與探討水飛薊預防肝纖維化之分子機制
論文名稱(外文):Establishment of an Animal Model of Thioacetamide(TAA)-Induced Liver Fibrosis and Investigation of the Molecular Mechanism of Silymarin in Liver Fibrosis Prevention
指導教授:邱智賢
指導教授(外文):Chih-Hsien Chiu
學位類別:碩士
校院名稱:國立臺灣大學
系所名稱:動物科學技術學研究所
學門:獸醫學門
學類:獸醫學類
論文種類:學術論文
論文出版年:2009
畢業學年度:97
語文別:中文
論文頁數:80
中文關鍵詞:肝纖維化水飛薊硫代乙醯胺
外文關鍵詞:Liver fibrosisSilymarinthioacetamide
相關次數:
  • 被引用被引用:0
  • 點閱點閱:726
  • 評分評分:
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
  肝臟纖維化與肝硬化為慢性肝病,主要由於慢性肝損傷造成,像是酗酒或慢性肝炎等。肝臟損傷會導致傷疤組織在健康的肝臟中累積,若造成肝纖維化或肝硬化的病因持續進行,肝臟最終將會走向肝硬化而使肝臟功能喪失。以往醫學研究認為肝硬化是不可逆的,然而在肝硬化形成初期,即肝纖維化初始時,其病情是仍處於可逆轉的情況。因此,本研究之目的是建立肝纖維化動物模式並找尋可能用來治療或預防肝纖維化的機制。本研究利用硫代乙醯胺(thioacetamide, TAA)以腹腔注射來誘發實驗動物肝臟纖維化。同時評估雄性ICR小鼠、BALB/c小鼠以及Wistar大鼠中哪種實驗動物較適合用於肝纖維化動物模式。初步結果顯示給予每公斤體重100毫克的TAA,可以誘發明顯的肝臟纖維化,並造成肝重體重比 (1.3-1.5倍)以及使血液中AST (1.6-2.4倍) 與ALT (3-4倍) 的上升。因此,應用TAA可成功的在三種實驗動物誘發肝臟損傷並造成肝纖維化。此外,本研究也比較了雄性與雌性ICR小鼠在誘發肝纖維化因性別所造成的差異,初步結果顯示雄性小鼠作為誘發肝纖維化動物模式為較佳的選擇。為了找尋治療或預防肝纖維化的機制,我們應用此動物模式評估薑黃素 (curcumin)、白藜蘆醇 (resveratrol) 以及水飛薊 (silymarin) 的護肝功效,就先前文獻已知此三種植化素已被證實具有抗發炎、抗氧化以及抗癌等特性。本試驗初步結果顯示,薑黃素、白藜蘆醇以及水飛薊均有預防肝損傷以及肝纖維化的功效,而水飛薊在本試驗中發現效果較為顯著,並已是現今臨床用藥且具有治療潛力;因此選擇此藥物進行後續肝纖維化預防之分子機制探討,本試驗利用半定量反轉錄聚合酵素連鎖反應分析NF-κB、AP-1以及KLF6等轉錄因子的mRNA量,結果發現TAA的處理可顯著增加此三種轉錄因子的表現,而在TAA與水飛薊共處理組中發現水飛薊處理可以減少AP-1以及KLF6的表現。肝細胞中的KLF6可調控其下游基因TGF-β1表現分泌,並刺激肝臟星狀細胞的活化並使細胞外基質堆積在肝臟中。這些結果顯示水飛薊保護肝臟減緩纖維化的機制可能是經由減少KLF6轉錄因子的表現,來抑制肝臟星狀細胞的活化以及減少肝臟纖維化的程度。總結以上結果,本試驗已成功建立肝纖維化齧齒類動物模式,並可應用於評估具預防肝纖維化功效之健康食品。而薑黃素、白藜蘆醇以及水飛薊應用於此一動物模式中均有預防肝損傷以及肝纖維化的功效。此外,水飛薊預防肝纖維化的機制可能經由抑制KLF6轉錄因子的表現,進而減少TGF-β1的表現量來抑制星狀細胞的活化並且減少肝臟組織中纖維的堆積。但其調控機制需要更進一步的探討。
Liver fibrosis and cirrhosis are chronic and progressive liver diseases that most often caused by chronic liver injuries, including alcoholism, hepatitis infection and other illnesses. Damage to the liver causes the development of scar tissue in the healthy liver tissue. If the underlying cause of liver fibrosis or cirrhosis continues, liver fibrosis and cirrhosis will progress and liver function will diminish. Cirrhosis is irreversible, but it is demonstrated liver fibrosis in animals and humans can be restored when collagen synthesis is inhibited. For this reason, the aim of this study is to establish an animal model of liver fibrosis and then find out the therapy pathway to cure liver fibrosis. The liver damage and fibrosis of animals were induced by intraperitoneal administration of thioacetamide (TAA), associated with increased oxidative stress and activation of hepatic stellate cells. Male ICR mice, BALB/c mice and Wistar rats were used to test which species may be more suitable to develop liver fibrosis. Preliminary results showed that intraperitoneal administration of 100 mg/kg bw TAA dosage would cause obvious liver fibrosis according to Masson’s Trichrome staining and increase liver weight (1.3 - 1.5 times), serum AST (1.6 - 2.4 times) and ALT (3 - 4 times) levels compared to those without TAA. This animal model successfully induced liver damage and fibrosis. Male and female ICR mice were also compared in this study for testing the gender differences on the development of iver fibrosis. In order to compare the therapy ability on liver fibrosis, curcumin, resveratrol and silymarin were used to evaluate the beneficial effects in this animal model. These phytochemicals were all reporterd with anti-inflammatory, anti-oxidant and anti-cancer properties. Our results showed that curcumin, resveratrol and silymarin all had beneficial effects on liver injury and fibrosis. Besides, silymarin had the most beneficial effects compared to curcumin and resveratrol, and it normalize liver weight, serum AST and ALT levels to those of animals without TAA treatments. In the late stage of liver fibrosis in this animal model, the mRNA levels of NF-κB, activator protein-1 (AP-1) and Kruppel-like factor 6 (KLF6) were detected by semi-quantitative RT-PCR. It showed that TAA treatments increased the expression of these 3 transcription factors. Taking of silymarin decreased the mRNA expression of AP-1 and KLF6, but not NF-κB, where KLF-6 would up-regulate the expression of TGF-β1 in hepatocyte. TGF-β1 then stimulated the activation of hepatic stellae cell and then caused extra cellular matrix accumulation in the liver. These results showed that silymarin may prevent liver fibrosis and reduce KLF6 pathway in mRNA levels, and then inhibit the activation of hepatic stellate cell and minimize hepatic fibrosis. In conclusion, the animal models of liver fibrosis were successfully established in ICR mice, BALB/c mice and Wistar rats. These models were helpful for further studies to test whether the health food have a hepatic protection or not. Curcumin, resveratrol and silymarin all had the beneficial effects in mouse model of liver fibrosis. Silymarin can prevent liver fibrosis and reduce KLF6 pathway. So far, this is the first finding in silymarin associated with KLF6 pathway, but the detailed pathway needs a further study to clarify.
目錄
摘要...................................................................................................................................I
Abstract............................................................................................................................III
目錄..................................................................................................................................V
圖次................................................................................................................................VII
表次.................................................................................................................................IX
I、 前言.......................................................................................................................1
II、 文獻探討
一、肝臟組織結構、生理功能及細胞組成.......................................................2
二、肝纖維化的成因以及病理機轉...................................................................6
三、肝纖維化動物模式的探討.........................................................................10
四、肝纖維化的治療以及臨床用藥水飛薊素Silymarin的護肝效果...........13
五、KLF6調控路徑...........................................................................................18
III、 研究動機.............................................................................................................22
IV、 材料與方法.........................................................................................................26
V、 結果......................................................................................................................34
一、TAA急性劑量試驗之存活率....................................................................34
二、TAA造成肝損傷之病理組織型態變化....................................................34
三、TAA於肝臟纖維化之影響........................................................................35
四、TAA誘發慢性肝纖維化對實驗動物肝重與體重比值之影響................36
五、TAA誘發慢性肝纖維化對實驗動物血液生化指數AST和ALT之影 響.............................................................................................................36
六、TAA誘發慢性肝纖維化對於雄性ICR小鼠血液生化值的影響...........37
七、三種植化素對肝纖維化動物模式中小鼠肝臟組織結構之影響.............37
八、三種植化素對肝纖維化動物模式中小鼠肝臟纖維化程度之影響.........38
九、三種植化素對肝纖維化動物模式中小鼠肝重體重比之影響.................38
十、三種植化素對肝纖維化動物模式中小鼠血液AST和ALT之影響......39
十一、水飛薊對肝纖維化動物模式中肝臟組織結構與肝纖維化程度之影 響.............................................................................................................39
十二、水飛薊對肝纖維化動物模式中肝重體重比與血液中AST和ALT之 影響.........................................................................................................40
十三、TAA與水飛薊對於MMP以及TIMP基因表現之影響.....................40
十四、TAA與水飛薊對於AP-1、KLF6以及NF-κB基因表現之影響.......41
十五、TAA與水飛薊對於TGF-β1、α-SMA以及COL-α1基因表現之影 響.............................................................................................................41
VI、 討論.....................................................................................................................42
一、建立TAA誘導動物肝損傷之肝纖維化動物模式...................................42
二、利用TAA誘發慢性肝纖維化動物模式評估相關植化素之護肝效果...43
三、探討水飛薊減緩肝纖維化形成之分子機制.............................................44
VII、 結論.....................................................................................................................64
VIII、 參考文獻.............................................................................................................65
邵婷。2008。什麼是肝癌。中華康網。取自 http://health.big5.enorth.com.cn/system/2008/02/25/002868081.shtml
Ahn, J., Lee, H., Kim, S. and Ha, T. 2007. Resveratrol inhibits TNF-α-induced changes of adipokines in 3T3-L1 adipocytes. Biochemical and Biophysical Research Communications, 364, 972-977.
Akbay, A., Cinar, K., Uzunalimoglu, O., Eranil, S., Yurdaydin, C., Bozkaya, H. and Bozdayi, M. 1999. Serum cytotoxin and oxidant stress markers in N-acetylcysteine treated thioacetamide hepatotoxicity of rats. Hum Exp Toxicol, 18, 669-76.
Albanis, E., Safadi, R. and Friedman, S. L. 2003. Treatment of hepatic fibrosis: almost there. Curr Gastroenterol Rep, 5, 48-56.
American Liver Foundation. 2006. Nonalcoholic Steatohepatitis. New York. Available at: http://digestive.niddk.nih.gov/ddiseases/pubs/nash/
Ammon, H. P. and Wahl, M. A. 1991. Pharmacology of Curcuma longa. Planta Med, 57, 1-7.
Arteel, G. E. 2003. Oxidants and antioxidants in alcohol-induced liver disease. Gastroenterology, 124, 778-90.
Arthur, M. J. 2000. Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. Am J Physiol Gastrointest Liver Physiol, 279, G245-9.
Barker, E. A. and Smuckler, E. A. 1974. Nonhepatic thioacetamide injury. II. The morphologic features of proximal renal tubular injury. Am J Pathol, 74, 575-90.
Batakov, E. A. 2001. Effect of Silybum marianum oil and legalon on lipid peroxidation and liver antioxidant systems in rats intoxicated with carbon tetrachloride. Eksp Klin Farmakol, 64, 53-5.
Bataller, R., Sancho-Bru, P., Gines, P. and Brenner, D. A. 2005. Liver fibrogenesis: a new role for the renin-angiotensin system. Antioxid Redox Signal, 7, 1346-55.
Bieker, J. J. 2001. Kruppel-like factors: three fingers in many pies. J Biol Chem, 276, 34355-8.
Boerth, J. and Strong, K. M. 2002. The clinical utility of milk thistle (Silybum marianum) in cirrhosis of the liver. J Herb Pharmacother, 2, 11-7.
Botella, L. M., Sanchez-Elsner, T., Sanz-Rodriguez, F., Kojima, S., Shimada, J., Guerrero-Esteo, M., Cooreman, M. P., Ratziu, V., Langa, C., Vary, C. P., Ramirez, J. R., Friedman, S. and Bernabeu, C. 2002. Transcriptional activation of endoglin and transforming growth factor-beta signaling components by cooperative interaction between Sp1 and KLF6: their potential role in the response to vascular injury. Blood, 100, 4001-10.
Bruck, R., Aeed, H., Avni, Y., Shirin, H., Matas, Z., Shahmurov, M., Avinoach, I., Zozulya, G., Weizman, N. and Hochman, A. 2004. Melatonin inhibits nuclear factor kappa B activation and oxidative stress and protects against thioacetamide induced liver damage in rats. J Hepatol, 40, 86-93.
Bruck, R., Aeed, H., Schey, R., Matas, Z., Reifen, R., Zaiger, G., Hochman, A. and Avni, Y. 2002. Pyrrolidine dithiocarbamate protects against thioacetamide-induced fulminant hepatic failure in rats. J Hepatol, 36, 370-7.
Bujanda, L., Garcia-Barcina, M., Juan, V., Bidaurrazaga, J., De Luco, M., Gutierrez-Stampa, M., Larzabal, M., Hijona, E., Sarasqueta, C., Echenique-Elizondo, M. and Arenas, J. 2006. 1471-230X-6-35.fm. BMC Gastroenterol, 6, 35.
Bunout, D., Hirsch, S., Petermann, M., de la Maza, M. P., Silva, G., Kelly, M., Ugarte, G. and Iturriaga, H. 1992. Controlled study of the effect of silymarin on alcoholic liver disease. Rev Med Chil, 120, 1370-5.
Burt, A. D. 1999. Pathobiology of hepatic stellate cells. J Gastroenterol, 34, 299-304.
Buzzelli, G., Moscarella, S., Giusti, A., Duchini, A., Marena, C. and Lampertico, M. 1993. A pilot study on the liver protective effect of silybin-phosphatidylcholine complex (IdB1016) in chronic active hepatitis. Int J Clin Pharmacol Ther Toxicol, 31, 456-60.
Celotti, E., Ferrarini, R., Zironi, R. and Conte, L. S. 1996. Resveratrol content of some wines obtained from dried Valpolicella grapes: Recioto and Amarone. J Chromatogr A, 730, 47-52.
Chen, C. T., Chu, C. J., Wang, T. F., Lu, R. H., Lee, F. Y., Chang, F. Y., Lin, H. C., Chan, C. C., Wang, S. S., Huang, H. C. and Lee, S. D. 2005. Evidence against a role for endotoxin in the hepatic encephalopathy of rats with thioacetamide-induced fulminant hepatic failure. J Gastroenterol Hepatol, 20, 450-5.
Chiambaretta, F., Blanchon, L., Rabier, B., Kao, W. W., Liu, J. J., Dastugue, B., Rigal, D. and Sapin, V. 2002. Regulation of corneal keratin-12 gene expression by the human Kruppel-like transcription factor 6. Invest Ophthalmol Vis Sci, 43, 3422-9.
Chieli, E. and Malvaldi, G. 1984. Role of the microsomal FAD-containing monooxygenase in the liver toxicity of thioacetamide S-oxide. Toxicology, 31, 41-52.
Dang, D. T., Pevsner, J. and Yang, V. W. 2000. The biology of the mammalian Kruppel-like family of transcription factors. Int J Biochem Cell Biol, 32, 1103-21.
Das, A., Fernandez-Zapico, M. E., Cao, S., Yao, J., Fiorucci, S., Hebbel, R. P., Urrutia, R. and Shah, V. H. 2006. Disruption of an SP2/KLF6 repression complex by SHP is required for farnesoid X receptor-induced endothelial cell migration. J Biol Chem, 281, 39105-13.
Dehmlow, C., Erhard, J. and de Groot, H. 1996. Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology, 23, 749-54.
Diez-Fernandez, C., Sanz, N., Alvarez, A. M., Zaragoza, A. and Cascales, M. 1998. Influence of aminoguanidine on parameters of liver injury and regeneration induced in rats by a necrogenic dose of thioacetamide. Br J Pharmacol, 125, 102-8.
Difeo, A., Martignetti, J. A. and Narla, G. 2008. The role of KLF6 and its splice variants in cancer therapy. Drug Resistance Updates, 1-7.
DiFeo, A., Narla, G., Camacho-Vanegas, O., Nishio, H., Rose, S. L., Buller, R. E., Friedman, S. L., Walsh, M. J. and Martignetti, J. A. 2006. E-cadherin is a novel transcriptional target of the KLF6 tumor suppressor. Oncogene, 25, 6026-31.
Dyroff, M. C. and Neal, R. A. 1981. Identification of the major protein adduct formed in rat liver after thioacetamide administration. Cancer Res, 41, 3430-5.
El Rouby, S., Rao, P. H. and Newcomb, E. W. 1997. Assignment of the human B-cell-derived (BCD1) proto-oncogene to 10p14-p15. Genomics, 43, 395-7.
Feher, J., Deak, G., Muzes, G., Lang, I., Niederland, V., Nekam, K. and Karteszi, M. 1989. Liver-protective action of silymarin therapy in chronic alcoholic liver diseases. Orv Hetil, 130, 2723-7.
Ferenci, P., Dragosics, B., Dittrich, H., Frank, H., Benda, L., Lochs, H., Meryn, S., Base, W. and Schneider, B. 1989. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol, 9, 105-13.
Flora, K., Hahn, M., Rosen, H. and Benner, K. 1998. Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol, 93, 139-43.
Forbes, S. J., Russo, F. P., Rey, V., Burra, P., Rugge, M., Wright, N. A. and Alison, M. R. 2004. A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis. Gastroenterology, 126, 955-63.
Fremont, L. 2000. Biological effects of resveratrol. Life Sci, 66, 663-73.
Friedman, H. Z., Langman, C. B. and Favus, M. J. 1985. Vitamin D metabolism and osteomalacia in cystic fibrosis. Gastroenterology, 88, 808-13.
Friedman, S. 2008. Hepatic fibrosis—Overview. Toxicology, 254, 120-129.
Friedman, S. L. 2000. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem, 275, 2247-50.
Friedman, S. L. 2003. Liver fibrosis -- from bench to bedside. J Hepatol, 38 Suppl 1, S38-53.
Friedman, S. L., Rockey, D. C., McGuire, R. F., Maher, J. J., Boyles, J. K. and Yamasaki, G. 1992. Isolated hepatic lipocytes and Kupffer cells from normal human liver: morphological and functional characteristics in primary culture. Hepatology, 15, 234-43.
Friedman, S. L., Wei, S. and Blaner, W. S. 1993. Retinol release by activated rat hepatic lipocytes: regulation by Kupffer cell-conditioned medium and PDGF. Am J Physiol, 264, G947-52.
Geerts, A. 2001. History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. Semin Liver Dis, 21, 311-35.
Gines, P., Cabrera, J., Guevara, M., Morillas, R., Ruiz del Arbol, L., Solae, R. and Soriano, G. 2004. Consensus document on the treatment of ascites, dilutional hyponatremia and hepatorenal syndrome in liver cirrhosis. Gastroenterol Hepatol, 27, 535-44.
Gressner, A. M., Lahme, B. and Brenzel, A. 1995. Molecular dissection of the mitogenic effect of hepatocytes on cultured hepatic stellate cells. Hepatology, 22, 1507-18.
He, Q., Osuchowski, M. F., Johnson, V. J. and Sharma, R. P. 2002. Physiological responses to a natural antioxidant flavonoid mixture, silymarin, in BALB/c mice: I induction of transforming growth factor beta1 and c-myc in liver with marginal effects on other genes. Planta Med, 68, 676-9.
Honda, H., Ikejima, K., Hirose, M., Yoshikawa, M., Lang, T., Enomoto, N., Kitamura, T., Takei, Y. and Sato, N. 2002. Leptin is required for fibrogenic responses induced by thioacetamide in the murine liver. Hepatology, 36, 12-21.
Hung, K. S., Lee, T. H., Chou, W. Y., Wu, C. L., Cho, C. L., Lu, C. N., Jawan, B. and Wang, C. H. 2005. Interleukin-10 gene therapy reverses thioacetamide-induced liver fibrosis in mice. Biochemical and Biophysical Research Communications, 336, 324-31.
Hunter, A. L., Holscher, M. A. and Neal, R. A. 1977. Thioacetamide-induced hepatic necrosis. I. Involvement of the mixed-function oxidase enzyme system. J Pharmacol Exp Ther, 200, 439-48.
Inuzuka, H., Nanbu-Wakao, R., Masuho, Y., Muramatsu, M., Tojo, H. and Wakao, H. 1999. Differential regulation of immediate early gene expression in preadipocyte cells through multiple signaling pathways. Biochem Biophys Res Commun, 265, 664-8.
Jacobs, B. P., Dennehy, C., Ramirez, G., Sapp, J. and Lawrence, V. A. 2002. Milk thistle for the treatment of liver disease: a systematic review and meta-analysis. Am J Med, 113, 506-15.
Johnson, V. J., Osuchowski, M. F., He, Q. and Sharma, R. P. 2002. Physiological responses to a natural antioxidant flavonoid mixture, silymarin, in BALB/c mice: II. alterations in thymic differentiation correlate with changes in c-myc gene expression. Planta Med, 68, 961-5.
Kadota, Y., Inoue, K., Tokunaga, R. and Taketani, S. 1996. Induction of peripheral-type benzodiazepine receptors in mouse brain following thioacetamide-induced acute liver failure. Life Sci, 58, 953-9.
Kallio, A., Guo, T., Lamminen, E., Seppanen, J., Kangas, L., Vaananen, H. K. and Harkonen, P. 2008. Estrogen and the selective estrogen receptor modulator (SERM) protection against cell death in estrogen receptor alpha and beta expressing U2OS cells. Mol Cell Endocrinol, 289, 38-48.
Kang, J. S., Morimura, K., Salim, E. I., Wanibuchi, H., Yamaguchi, S. and Fukushima, S. 2005. Persistence of liver cirrhosis in association with proliferation of nonparenchymal cells and altered location of alpha-smooth muscle actin-positive cells. Toxicol Pathol, 33, 329-35.
Kim, Y., Ratziu, V., Choi, S. G., Lalazar, A., Theiss, G., Dang, Q., Kim, S. J. and Friedman, S. L. 1998. Transcriptional activation of transforming growth factor beta1 and its receptors by the Kruppel-like factor Zf9/core promoter-binding protein and Sp1. Potential mechanisms for autocrine fibrogenesis in response to injury. J Biol Chem, 273, 33750-8.
Kittur, S., Wilasrusmee, S., Pedersen, W. A., Mattson, M. P., Straube-West, K., Wilasrusmee, C., Lubelt, B. and Kittur, D. S. 2002. Neurotrophic and neuroprotective effects of milk thistle (Silybum marianum) on neurons in culture. J Mol Neurosci, 18, 265-9.
Koch, H. P. and Ritschel, W. A. 1981. Bioavailability of silymarin, I: Volumes of distribution of silybin, silydianin, and silychristin from in-vitro data (author''s transl). Arch Pharm (Weinheim), 314, 515-7.
Kojima, S., Hayashi, S., Shimokado, K., Suzuki, Y., Shimada, J., Crippa, M. P. and Friedman, S. L. 2000. Transcriptional activation of urokinase by the Kruppel-like factor Zf9/COPEB activates latent TGF-beta1 in vascular endothelial cells. Blood, 95, 1309-16.
Koritschoner, N. P., Bocco, J. L., Panzetta-Dutari, G. M., Dumur, C. I., Flury, A. and Patrito, L. C. 1997. A novel human zinc finger protein that interacts with the core promoter element of a TATA box-less gene. J Biol Chem, 272, 9573-80.
Kravchenko, L. V., Avren''eva, L. I. and Tutel''ian, V. A. 2000. Effects of bioflavonoids on the toxicity of T-toxin in rats. A biochemical study. Vopr Pitan, 69, 20-3.
Kremer-Tal, S., Narla, G., Chen, Y., Hod, E., DiFeo, A., Yea, S., Lee, J. S., Schwartz, M., Thung, S. N., Fiel, I. M., Banck, M., Zimran, E., Thorgeirsson, S. S., Mazzaferro, V., Bruix, J., Martignetti, J. A., Llovet, J. M. and Friedman, S. L. 2007. Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. J Hepatol, 46, 645-54.
Kweon, Y. O., Paik, Y. H., Schnabl, B., Qian, T., Lemasters, J. J. and Brenner, D. A. 2003. Gliotoxin-mediated apoptosis of activated human hepatic stellate cells. J Hepatol, 39, 38-46.
Leclercq, I., Farrell, G., Sempoux, C., Pena, A. and Horsmans, Y. 2004. Curcumin inhibits NF-κB activation and reduces the severity of experimental steatohepatitis in mice. Journal of Hepatology, 41, 926-934.
Lee, D. Y. and Liu, Y. 2003. Molecular structure and stereochemistry of silybin A, silybin B, isosilybin A, and isosilybin B, Isolated from Silybum marianum (milk thistle). J Nat Prod, 66, 1171-4.
Lee, S. O., Jeong, Y. J., Im, H. G., Kim, C. H., Chang, Y. C. and Lee, I. S. 2007. Silibinin suppresses PMA-induced MMP-9 expression by blocking the AP-1 activation via MAPK signaling pathways in MCF-7 human breast carcinoma cells. Biochem Biophys Res Commun, 354, 165-71.
Li, D., Yea, S., Li, S., Chen, Z., Narla, G., Banck, M., Laborda, J., Tan, S., Friedman, J. M., Friedman, S. L. and Walsh, M. J. 2005. Kruppel-like factor-6 promotes preadipocyte differentiation through histone deacetylase 3-dependent repression of DLK1. J Biol Chem, 280, 26941-52.
Li, X., Benjamin, I. S. and Alexander, B. 2002. Reproducible production of thioacetamide-induced macronodular cirrhosis in the rat with no mortality. J Hepatol, 36, 488-93.
Lichtinghagen, R., Michels, D., Haberkorn, C. I., Arndt, B., Bahr, M., Flemming, P., Manns, M. P. and Boeker, K. H. 2001. Matrix metalloproteinase (MMP)-2, MMP-7, and tissue inhibitor of metalloproteinase-1 are closely related to the fibroproliferative process in the liver during chronic hepatitis C. J Hepatol, 34, 239-47.
Lieber, C., Leo, M., Cao, Q., Ren, C. and DeCarli, L. 2003. Silymarin retards the progression of alcohol-induced hepatic fibrosis in baboons. Journal of Clinical Gastroenterology, 37, 336.
Mangipudy, R. S., Chanda, S. and Mehendale, H. M. 1995. Tissue repair response as a function of dose in thioacetamide hepatotoxicity. Environ Health Perspect, 103, 260-7.
Manna, S. K., Mukhopadhyay, A., Van, N. T. and Aggarwal, B. B. 1999. Silymarin suppresses TNF-induced activation of NF-kappa B, c-Jun N-terminal kinase, and apoptosis. J Immunol, 163, 6800-9.
Matsumoto, N., Kubo, A., Liu, H., Akita, K., Laub, F., Ramirez, F., Keller, G. and Friedman, S. L. 2006. Developmental regulation of yolk sac hematopoiesis by Kruppel-like factor 6. Blood, 107, 1357-65.
Matsuoka, A., Kodama, Y., Fukuhara, K., Honda, S., Hayashi, M., Sai, K., Hasebe, M. and Fujiwara, Y. 2008. A pilot study of evaluation of the antioxidative activity of resveratrol and its analogue in a 6-month feeding test in young adult mice. Food Chem Toxicol, 46, 1125-30.
Merika, M. and Orkin, S. H. 1995. Functional synergy and physical interactions of the erythroid transcription factor GATA-1 with the Kruppel family proteins Sp1 and EKLF. Mol Cell Biol, 15, 2437-47.
Miele, L., Beale, G., Patman, G., Nobili, V., Leathart, J., Grieco, A., Abate, M., Friedman, S., Narla, G. and Bugianesi, E. 2008. The Kruppel-Like Factor 6 Genotype Is Associated With Fibrosis in Nonalcoholic Fatty Liver Disease. Gastroenterology, 135, 282-291.e1.
Miller, I. J. and Bieker, J. J. 1993. A novel, erythroid cell-specific murine transcription factor that binds to the CACCC element and is related to the Kruppel family of nuclear proteins. Mol Cell Biol, 13, 2776-86.
Moreira, E., Fontana, L., Periago, J. L., Sanchez De Medina, F. and Gil, A. 1995. Changes in fatty acid composition of plasma, liver microsomes, and erythrocytes in liver cirrhosis induced by oral intake of thioacetamide in rats. Hepatology, 21, 199-206.
Muller, A., Machnik, F., Zimmermann, T. and Schubert, H. 1988. Thioacetamide-induced cirrhosis-like liver lesions in rats--usefulness and reliability of this animal model. Exp Pathol, 34, 229-36.
Mulrow, C., Lawrence, V., Jacobs, B., Dennehy, C., Sapp, J., Ramirez, G., Aguilar, C., Montgomery, K., Morbidoni, L., Arterburn, J. M., Chiquette, E., Harris, M., Mullins, D., Vickers, A. and Flora, K. 2000. Milk thistle: effects on liver disease and cirrhosis and clinical adverse effects. Evid Rep Technol Assess (Summ), 1-3.
Nanji, A., Jokelainen, K., Tipoe, G., Rahemtulla, A., Thomas, P. and Dannenberg, A. 2003. Curcumin prevents alcohol-induced liver disease in rats by inhibiting the expression of NF-κB-dependent genes. American Journal of Physiology- Gastrointestinal and Liver Physiology, 284, 321-327.
Narla, G. 2001. KLF6, a Candidate Tumor Suppressor Gene Mutated in Prostate Cancer. Science, 294, 2563-2566.
Okada, K., Wangpoengtrakul, C., Tanaka, T., Toyokuni, S., Uchida, K. and Osawa, T. 2001. Curcumin and especially tetrahydrocurcumin ameliorate oxidative stress-induced renal injury in mice. J Nutr, 131, 2090-5.
Okano, J., Opitz, O. G., Nakagawa, H., Jenkins, T. D., Friedman, S. L. and Rustgi, A. K. 2000. The Kruppel-like transcriptional factors Zf9 and GKLF coactivate the human keratin 4 promoter and physically interact. FEBS Lett, 473, 95-100.
Okuyama, H., Nakamura, H., Shimahara, Y., Uyama, N., Kwon, Y. W., Kawada, N., Yamaoka, Y. and Yodoi, J. 2005. Overexpression of thioredoxin prevents thioacetamide-induced hepatic fibrosis in mice. J Hepatol, 42, 117-23.
Otto, D. A. and Veech, R. L. 1980. Isolation of a lipocyte-rich fraction from rat liver nonparenchymal cells. Adv Exp Med Biol, 132, 509-17.
Pallottini, V., Martini, C., Bassi, A. M., Romano, P., Nanni, G. and Trentalance, A. 2006. Rat HMGCoA reductase activation in thioacetamide-induced liver injury is related to an increased reactive oxygen species content. J Hepatol, 44, 368-74.
Pares, A., Planas, R., Torres, M., Caballeria, J., Viver, J. M., Acero, D., Panes, J., Rigau, J., Santos, J. and Rodes, J. 1998. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. J Hepatol, 28, 615-21.
Pinzani, M., Gesualdo, L., Sabbah, G. M. and Abboud, H. E. 1989. Effects of platelet-derived growth factor and other polypeptide mitogens on DNA synthesis and growth of cultured rat liver fat-storing cells. J Clin Invest, 84, 1786-93.
Piscitelli, S. C., Formentini, E., Burstein, A. H., Alfaro, R., Jagannatha, S. and Falloon, J. 2002. Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers. Pharmacotherapy, 22, 551-6.
Popper, H. and Uenfriend, S. 1970. Hepatic fibrosis. Correlation of biochemical and morphologic investigations. Am J Med, 49, 707-21.
Porter, W. R., Gudzinowicz, M. J. and Neal, R. A. 1979. Thioacetamide-induced hepatic necrosis. II. Pharmacokinetics of thioacetamide and thioacetamide-S-oxide in the rat. J Pharmacol Exp Ther, 208, 386-91.
Porter, W. R. and Neal, R. A. 1978. Metabolism of thioacetamide and thioacetamide S-oxide by rat liver microsomes. Drug Metab Dispos, 6, 379-88.
Rainone, F. 2005. Milk thistle. Am Fam Physician, 72, 1285-8.
Ramadori, G. and Saile, B. 2004. Inflammation, damage repair, immune cells, and liver fibrosis: specific or nonspecific, this is the question. Gastroenterology, 127, 997-1000.
Rather, L. J. 1951. Experimental alteration of nuclear and cytoplasmic components of the liver cell with thioacetamide. I. Early onset and reversibility of volume changes of the nucleolus, nucleus and cytoplasm. Bull Johns Hopkins Hosp, 88, 38-58.
Ratziu, V., Lalazar, A., Wong, L., Dang, Q., Collins, C., Shaulian, E., Jensen, S. and Friedman, S. 1998. Zf9, a Kruppel-like transcription factor up-regulated in vivo during early hepatic fibrosis. Proceedings of the National Academy of Sciences, 95, 9500-9505.
Regimbeau, J. M., Abdalla, E. K., Vauthey, J. N., Lauwers, G. Y., Durand, F., Nagorney, D. M., Ikai, I., Yamaoka, Y. and Belghiti, J. 2004a. Risk factors for early death due to recurrence after liver resection for hepatocellular carcinoma: results of a multicenter study. J Surg Oncol, 85, 36-41.
Regimbeau, J. M., Colombat, M., Mognol, P., Durand, F., Abdalla, E., Degott, C., Degos, F., Farges, O. and Belghiti, J. 2004b. Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transpl, 10, S69-73.
Rockey, D. C., Boyles, J. K., Gabbiani, G. and Friedman, S. L. 1992. Rat hepatic lipocytes express smooth muscle actin upon activation in vivo and in culture. J Submicrosc Cytol Pathol, 24, 193-203.
Saller, R., Meier, R. and Brignoli, R. 2001. The use of silymarin in the treatment of liver diseases. Drugs, 61, 2035.
Salmi, H. A. and Sarna, S. 1982. Effect of silymarin on chemical, functional, and morphological alterations of the liver. A double-blind controlled study. Scand J Gastroenterol, 17, 517-21.
Sanz, N., Diez-Fernandez, C., Fernandez-Simon, L., Alvarez, A. and Cascales, M. 1995. Relationship between antioxidant systems, intracellular thiols and DNA ploidy in liver of rats during experimental cirrhogenesis. Carcinogenesis, 16, 1585-93.
Sarkar, K. and Sil, P. C. 2006. A 43 kDa protein from the herb Cajanus indicus L. protects thioacetamide induced cytotoxicity in hepatocytes. Toxicol In Vitro, 20, 634-40.
Senoo, H. 2004. Structure and function of hepatic stellate cells. Med Electron Microsc, 37, 3-15.
Shankar, K., Vaidya, V. S., Wang, T., Bucci, T. J. and Mehendale, H. M. 2003. Streptozotocin-induced diabetic mice are resistant to lethal effects of thioacetamide hepatotoxicity. Toxicol Appl Pharmacol, 188, 122-34.
Sonnenbichler, J., Scalera, F., Sonnenbichler, I. and Weyhenmeyer, R. 1999. Stimulatory effects of silibinin and silicristin from the milk thistle Silybum marianum on kidney cells. J Pharmacol Exp Ther, 290, 1375-83.
Soyer, M. T., Ceballos, R. and Aldrete, J. S. 1976. Reversibility of severe hepatic damage caused by jejunoileal bypass after re-establishment of normal intestinal continuity. Surgery, 79, 601-4.
Starkel, P., Sempoux, C., Leclercq, I., Herin, M., Deby, C., Desager, J. and Horsmans, Y. 2003. Oxidative stress, KLF6 and transforming growth factor-beta up-regulation differentiate non-alcoholic steatohepatitis progressing to fibrosis from uncomplicated steatosis in rats. Journal of Hepatology, 39, 538.
Stickel, F., Brinkhaus, B., Krahmer, N., Seitz, H. K., Hahn, E. G. and Schuppan, D. 2002. Antifibrotic properties of botanicals in chronic liver disease. Hepatogastroenterology, 49, 1102-8.
Sur, I., Unden, A. B. and Toftgard, R. 2002. Human Kruppel-like factor5/KLF5: synergy with NF-kappaB/Rel factors and expression in human skin and hair follicles. Eur J Cell Biol, 81, 323-34.
Swapna, I., Sathyasaikumar, K. V., Murthy Ch, R., Dutta-Gupta, A. and Senthilkumaran, B. 2006. Changes in cerebral membrane lipid composition and fluidity during thioacetamide-induced hepatic encephalopathy. J Neurochem, 98, 1899-907.
Szilard, S., Szentgyorgyi, D. and Demeter, I. 1988. Protective effect of Legalon in workers exposed to organic solvents. Acta Med Hung, 45, 249-56.
Tager, M., Dietzmann, J., Thiel, U., Hinrich Neumann, K. and Ansorge, S. 2001. Restoration of the cellular thiol status of peritoneal macrophages from CAPD patients by the flavonoids silibinin and silymarin. Free Radic Res, 34, 137-51.
Trinchet, J. C., Coste, T., Levy, V. G., Vivet, F., Duchatelle, V., Legendre, C., Gotheil, C. and Beaugrand, M. 1989. Treatment of alcoholic hepatitis with silymarin. A double-blind comparative study in 116 patients. Gastroenterol Clin Biol, 13, 120-4.
Tsukamoto, H., Matsuoka, M. and French, S. W. 1990. Experimental models of hepatic fibrosis: a review. Semin Liver Dis, 10, 56-65.
Valenzuela, A. and Garrido, A. 1994. Biochemical bases of the pharmacological action of the flavonoid silymarin and of its structural isomer silibinin. Biol Res, 27, 105-12.
von Schonfeld, J., Weisbrod, B. and Muller, M. K. 1997. Silibinin, a plant extract with antioxidant and membrane stabilizing properties, protects exocrine pancreas from cyclosporin A toxicity. Cell Mol Life Sci, 53, 917-20.
Wallace, K., Burt, A. and Wright, M. 2008. Liver fibrosis. Biochem. J., 411, 1.
Wang, C. H., Jawan, B., Lee, T. H., Hung, K. S., Chou, W. Y., Lu, C. N., Liu, J. K. and Chen, Y. J. 2004. Single injection of naked plasmid encoding alpha-melanocyte-stimulating hormone protects against thioacetamide-induced acute liver failure in mice. Biochemical and Biophysical Research Communications, 322, 153-61.
Wang, C. H., Lee, T. H., Lu, C. N., Chou, W. Y., Hung, K. S., Concejero, A. M. and Jawan, B. 2006. Electroporative alpha-MSH gene transfer attenuates thioacetamide-induced murine hepatic fibrosis by MMP and TIMP modulation. Gene Ther, 13, 1000-9.
Wasser, S. and Tan, C. E. 1999. Experimental models of hepatic fibrosis in the rat. Ann Acad Med Singapore, 28, 109-11.
Wilasrusmee, C., Kittur, S., Shah, G., Siddiqui, J., Bruch, D., Wilasrusmee, S. and Kittur, D. S. 2002. Immunostimulatory effect of Silybum Marianum (milk thistle) extract. Med Sci Monit, 8, BR439-43.
Zaragoza, A., Andres, D., Sarrion, D. and Cascales, M. 2000. Potentiation of thioacetamide hepatotoxicity by phenobarbital pretreatment in rats. Inducibility of FAD monooxygenase system and age effect. Chem Biol Interact, 124, 87-101.
Zhang, D., Zhang, X. L., Michel, F. J., Blum, J. L., Simmen, F. A. and Simmen, R. C. 2002. Direct interaction of the Kruppel-like family (KLF) member, BTEB1, and PR mediates progesterone-responsive gene expression in endometrial epithelial cells. Endocrinology, 143, 62-73.
Zhao, J. L., Austen, K. F. and Lam, B. K. 2000. Cell-specific transcription of leukotriene C(4) synthase involves a Kruppel-like transcription factor and Sp1. J Biol Chem, 275, 8903-10.
Zi, X., Mukhtar, H. and Agarwal, R. 1997. Novel cancer chemopreventive effects of a flavonoid antioxidant silymarin: inhibition of mRNA expression of an endogenous tumor promoter TNF alpha. Biochem Biophys Res Commun, 239, 334-9.
Zuber, R., Modriansky, M., Dvorak, Z., Rohovsky, P., Ulrichova, J., Simanek, V. and Anzenbacher, P. 2002. Effect of silybin and its congeners on human liver microsomal cytochrome P450 activities. Phytother Res, 16, 632-8.
QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top
無相關期刊